2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Breast Neoplasms
8
Prostatic Neoplasms
5
Polycystic Ovary Syndrome
5
Multiple Myeloma
5
Colorectal Neoplasms
5
Small Cell Lung Carcinoma
4
Rectal Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Fibrosis
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Hepatocellular
2
Breast Carcinoma In Situ
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Venous Thromboembolism
1
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Thrombosis
1
Sprains and Strains
1
Smoldering Multiple Myeloma
1
Sepsis
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Interventions
Sunitinib
145
Nivolumab
144
pembrolizumab
132
Sorafenib
84
Bevacizumab
77
Everolimus
74
cabozantinib
71
pazopanib
65
Axitinib
65
Ipilimumab
62
aldesleukin
52
Magnetic Resonance Spectroscopy
45
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
37
Specimen Handling
36
Radiosurgery
36
Interferon-alpha
32
atezolizumab
30
temsirolimus
27
belzutifan
24
Gemcitabine
23
fludarabine phosphate
22
avelumab
22
Radiotherapy
19
Interferon alpha-2
19
Biopsy
18
fludarabine
17
durvalumab
17
Nephrectomy
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Simvastatin
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled